Amyloid-beta Targeted Therapeutic Approaches for Alzheimer’s Disease:
Long Road Ahead

doi:10.2174/1389450123666220421124030
摘要

阿尔茨海默病（AD）是一种进行性神经退行性疾病，其特征在于记忆障碍和认知能力下降。AD的明显病理特征仍然是淀粉样蛋白斑块和神经原纤维缠结。AD的疾病改善疗法的发展一直在发展，具有挑战性，几乎所有药物都流产了。淀粉样蛋白级联概念受到质疑，因为各种淀粉样蛋白靶向前景的失败。尽管如此，靶向淀粉样蛋白β（Aβ）活性免疫疗法提供了一些积极的结果来支持这一假设和这些假设的临床试验，这些候选药物的临床试验正在进行中。在这篇综述中，我们描述了治疗策略的最新进展关于淀粉样蛋白的处理，并评估每种治疗策略的优缺点。我们还重点介绍最热门免疫疗法的现状，探讨未来的发展方向。
关键词: 阿尔茨海默病，β淀粉样蛋白，临床研究，免疫治疗和药物开发，神经退行性疾病。
« Previous Next »
图形摘要

[1] 
Scheltens P, Blennow K, Breteler MM, et al. Alzheimer’s disease. Lancet  2016; 388(10043): 505-17.
[http://dx.doi.org/10.1016/S0140-6736(15)01124-1] [PMID:  26921134] 
[2] 
Matthews KA, Xu W, Gaglioti AH, et al. Racial and ethnic estimates of Alzheimer’s disease and related dementias in the United States (2015-2060) in adults aged ≥65 years. Alzheimers Dement  2019; 15(1): 17-24.
[http://dx.doi.org/10.1016/j.jalz.2018.06.3063] [PMID:  30243772] 
[3] 
 World Alzheimer Report 2018. Available from: https://www. alzint.org/resource/world-alzheimer-report-2018/ Accessed on September 27, 2021.
[4] 
Long JM, Holtzman DM. Alzheimer disease: An update on pathobiology and treatment strategies. Cell  2019; 179(2): 312-39.
[http://dx.doi.org/10.1016/j.cell.2019.09.001] [PMID:  31564456] 
[5] 
Elmaleh DR, Farlow MR, Conti PS, Tompkins RG, Kundakovic L, Tanzi RE. Developing effective alzheimer’s disease therapies: Clinical experience and future directions. J Alzheimers Dis  2019; 71(3): 715-32.
[http://dx.doi.org/10.3233/JAD-190507] [PMID:  31476157] 
[6] 
Cline EN, Bicca MA, Viola KL, Klein WL. The Amyloid-β oligomer hypothesis: Beginning of the third decade. J Alzheimers Dis  2018; 64(s1): S567-610.
[http://dx.doi.org/10.3233/JAD-179941] [PMID:  29843241] 
[7] 
Syed YY. Sodium oligomannate: First approval. Drugs  2020; 80(4): 441-4.
[http://dx.doi.org/10.1007/s40265-020-01268-1] [PMID:  32020555] 
[8] 
Vaz M, Silvestre S. Alzheimer’s disease: Recent treatment strategies. Eur J Pharmacol  2020; 887: 173554.
[http://dx.doi.org/10.1016/j.ejphar.2020.173554] [PMID:  32941929] 
[9] 
Becker RE, Greig NH. Can we prevent dementia and not prevent neurons from dying? J Alzheimers Dis  2019; 68(2): 489-92.
[http://dx.doi.org/10.3233/JAD-181300] [PMID:  30814363] 
[10] 
Imbimbo BP, Ippati S, Watling M. Should drug discovery scientists still embrace the amyloid hypothesis for Alzheimer’s disease or should they be looking elsewhere? Expert Opin Drug Discov  2020; 15(11): 1241-51.
[http://dx.doi.org/10.1080/17460441.2020.1793755] [PMID:  32686970] 
[11] 
Mullane K, Williams M. Alzheimer’s disease (AD) therapeutics - 1: Repeated clinical failures continue to question the amyloid hypothesis of AD and the current understanding of AD causality. Biochem Pharmacol  2018; 158: 359-75.
[http://dx.doi.org/10.1016/j.bcp.2018.09.026] [PMID:  30273553] 
[12] 
Alexander GC, Emerson S, Kesselheim AS. Evaluation of aducanumab for alzheimer disease: Scientific evidence and regulatory review involving efficacy, safety, and futility. JAMA  2021; 325(17): 1717-8.
[http://dx.doi.org/10.1001/jama.2021.3854] [PMID:  33783469] 
[13] 
Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer’s disease: Progress and problems on the road to therapeutics. Science  2002; 297(5580): 353-6.
[http://dx.doi.org/10.1126/science.1072994] [PMID:  12130773] 
[14] 
Faustino C, Rijo P, Reis CP. Nanotechnological strategies for nerve growth factor delivery: Therapeutic implications in Alzheimer’s disease. Pharmacol Res  2017; 120: 68-87.
[http://dx.doi.org/10.1016/j.phrs.2017.03.020] [PMID:  28351757] 
[15] 
Jan A, Gokce O, Luthi-Carter R, Lashuel HA. The ratio of monomeric to aggregated forms of Abeta40 and Abeta42 is an important determinant of amyloid-beta aggregation, fibrillogenesis, and toxicity. J Biol Chem  2008; 283(42): 28176-89.
[http://dx.doi.org/10.1074/jbc.M803159200] [PMID:  18694930] 
[16] 
Ferreira ST, Lourenco MV, Oliveira MM, De Felice FG. Soluble amyloid-β oligomers as synaptotoxins leading to cognitive impairment in Alzheimer’s disease. Front Cell Neurosci  2015; 9: 191.
[http://dx.doi.org/10.3389/fncel.2015.00191] [PMID:  26074767] 
[17] 
Wang JZ, Xia YY, Grundke-Iqbal I, Iqbal K. Abnormal hyperphosphorylation of tau: Sites, regulation, and molecular mechanism of neurofibrillary degeneration. J Alzheimers Dis  2013; 33(s1)(Suppl. 1): S123-39.
[http://dx.doi.org/10.3233/JAD-2012-129031] [PMID:  22710920] 
[18] 
Selkoe DJ. Treatments for Alzheimer’s disease emerge. Science  2021; 373(6555): 624-6.
[http://dx.doi.org/10.1126/science.abi6401] [PMID:  34353940] 
[19] 
Kumar D, Ganeshpurkar A, Kumar D, Modi G, Gupta SK, Singh SK. Secretase inhibitors for the treatment of Alzheimer’s disease: Long road ahead. Eur J Med Chem  2018; 148: 436-52.
[http://dx.doi.org/10.1016/j.ejmech.2018.02.035] [PMID:  29477076] 
[20] 
Miranda A, Montiel E, Ulrich H, Paz C. Selective secretase targeting for alzheimer’s disease therapy. J Alzheimers Dis  2021; 81(1): 1-17.
[http://dx.doi.org/10.3233/JAD-201027] [PMID:  33749645] 
[21] 
Hampel H, Vassar R, De Strooper B, et al. The β-secretase BACE1 in alzheimer’s disease. Biol Psychiatry  2021; 89(8): 745-56.
[http://dx.doi.org/10.1016/j.biopsych.2020.02.001] [PMID:  32223911] 
[22] 
May PC, Dean RA, Lowe SL, et al. Robust central reduction of amyloid-β in humans with an orally available, non-peptidic β-secretase inhibitor. J Neurosci  2011; 31(46): 16507-16.
[http://dx.doi.org/10.1523/JNEUROSCI.3647-11.2011] [PMID:  22090477] 
[23] 
Barão S, Moechars D, Lichtenthaler SF, De Strooper B. BACE1 physiological functions may limit its use as therapeutic target for alzheimer’s disease. Trends Neurosci  2016; 39(3): 158-69.
[http://dx.doi.org/10.1016/j.tins.2016.01.003] [PMID:  26833257] 
[24] 
May PC, Willis BA, Lowe SL, et al. The potent BACE1 inhibitor LY2886721 elicits robust central Aβ pharmacodynamic responses in mice, dogs, and humans. J Neurosci  2015; 35(3): 1199-210.
[http://dx.doi.org/10.1523/JNEUROSCI.4129-14.2015] [PMID:  25609634] 
[25] 
Bernier F, Sato Y, Matijevic M, et al. Clinical study of E2609, a novel BACE1 inhibitor, demonstrates target engagement and inhibition of BACE1 activity in CSF. Alzheimers Dement  2013; 9(4): 886.
[http://dx.doi.org/10.1016/j.jalz.2013.08.244] 
[26] 
Panza F, Lozupone M, Solfrizzi V, et al. BACE inhibitors in clinical development for the treatment of Alzheimer’s disease. Expert Rev Neurother  2018; 18(11): 847-57.
[http://dx.doi.org/10.1080/14737175.2018.1531706] [PMID:  30277096] 
[27] 
Moussa-Pacha NM, Abdin SM, Omar HA, Alniss H, Al-Tel TH. BACE1 inhibitors: Current status and future directions in treating Alzheimer’s disease. Med Res Rev  2020; 40(1): 339-84.
[http://dx.doi.org/10.1002/med.21622] [PMID:  31347728] 
[28] 
Dobrowolska Zakaria JA, Vassar RJ. A promising, novel, and unique BACE1 inhibitor emerges in the quest to prevent Alzheimer’s disease. EMBO Mol Med  2018; 10(11): e9717.
[http://dx.doi.org/10.15252/emmm.201809717] [PMID:  30322841] 
[29] 
Neumann U, Ufer M, Jacobson LH, et al. The BACE-1 inhibitor CNP520 for prevention trials in Alzheimer’s disease. EMBO Mol Med  2018; 10(11): e9316.
[http://dx.doi.org/10.15252/emmm.201809316] [PMID:  30224383] 
[30] 
Neumann U, Jacobson LH, Perrot L, Beltz K, Shimshek DR. Preclinical pharmacology of bace inhibitor CNP520. Alzhmer’s & dementia. J Alzhmer’s Assoc  2016; 12(7): 433-4.
[31] 
Lopez Lopez C, Tariot PN, Caputo A, et al. The Alzheimer’s Prevention Initiative Generation Program: Study design of two randomized controlled trials for individuals at risk for clinical onset of Alzheimer’s disease. Alzheimers Dement (N Y)  2019; 5(1): 216-27.
[http://dx.doi.org/10.1016/j.trci.2019.02.005] [PMID:  31211217] 
[32] 
Yagishita S, Morishima-Kawashima M, Ishiura S, Ihara Y. Abeta46 is processed to Abeta40 and Abeta43, but not to Abeta42, in the low density membrane domains. J Biol Chem  2008; 283(2): 733-8.
[http://dx.doi.org/10.1074/jbc.M707103200] [PMID:  18024430] 
[33] 
Henley DB, May PC, Dean RA, Siemers ER. Development of semagacestat (LY450139), a functional gamma-secretase inhibitor, for the treatment of Alzheimer’s disease. Expert Opin Pharmacother  2009; 10(10): 1657-64.
[http://dx.doi.org/10.1517/14656560903044982] [PMID:  19527190] 
[34] 
Siemers E, Skinner M, Dean RA, et al. Safety, tolerability, and changes in amyloid beta concentrations after administration of a gamma-secretase inhibitor in volunteers. Clin Neuropharmacol  2005; 28(3): 126-32.
[http://dx.doi.org/10.1097/01.wnf.0000167360.27670.29] [PMID:  15965311] 
[35] 
Fleisher AS, Raman R, Siemers ER, et al. Phase 2 safety trial targeting amyloid beta production with a gamma-secretase inhibitor in Alzheimer disease. Arch Neurol  2008; 65(8): 1031-8.
[http://dx.doi.org/10.1001/archneur.65.8.1031] [PMID:  18695053] 
[36] 
Doody RS, Raman R, Farlow M, et al. A phase 3 trial of semagacestat for treatment of Alzheimer’s disease. N Engl J Med  2013; 369(4): 341-50.
[http://dx.doi.org/10.1056/NEJMoa1210951] [PMID:  23883379] 
[37] 
De Strooper B. Lessons from a failed γ-secretase Alzheimer trial. Cell  2014; 159(4): 721-6.
[http://dx.doi.org/10.1016/j.cell.2014.10.016] [PMID:  25417150] 
[38] 
Albright CF, Dockens RC, Meredith JE Jr, et al. Pharmacodynamics of selective inhibition of γ-secretase by avagacestat. J Pharmacol Exp Ther  2013; 344(3): 686-95.
[http://dx.doi.org/10.1124/jpet.112.199356] [PMID:  23275065] 
[39] 
Coric V, Salloway S, van Dyck CH, et al. Targeting prodromal alzheimer disease with avagacestat: A randomized clinical trial. JAMA Neurol  2015; 72(11): 1324-33.
[http://dx.doi.org/10.1001/jamaneurol.2015.0607] [PMID:  26414022] 
[40] 
Cummings J, Lee G, Ritter A, Sabbagh M, Zhong K. Alzheimer’s disease drug development pipeline: 2020. Alzheimers Dement (N Y)  2020; 6(1): e12050.
[http://dx.doi.org/10.1002/trc2.12050] [PMID:  32695874] 
[41] 
Bursavich MG, Harrison BA, Blain JF. Gamma secretase modulators: New alzheimer’s drugs on the horizon? J Med Chem  2016; 59(16): 7389-409.
[http://dx.doi.org/10.1021/acs.jmedchem.5b01960] [PMID:  27007185] 
[42] 
Zheng D, Shuai X, Li Y, et al. Novel flurbiprofen derivatives with improved brain delivery: Synthesis, in vitro and in vivo evaluations. Drug Deliv  2016; 23(7): 2183-92.
[http://dx.doi.org/10.3109/10717544.2014.954165] [PMID:  25182481] 
[43] 
Green RC, Schneider LS, Amato DA, et al. Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease: A randomized controlled trial. JAMA  2009; 302(23): 2557-64.
[http://dx.doi.org/10.1001/jama.2009.1866] [PMID:  20009055] 
[44] 
Imbimbo BP, Frigerio E, Breda M, et al. Pharmacokinetics and pharmacodynamics of CHF5074 after short-term administration in healthy subjects. Alzheimer Dis Assoc Disord  2013; 27(3): 278-86.
[http://dx.doi.org/10.1097/WAD.0b013e3182622ace] [PMID:  22922591] 
[45] 
Lichtenthaler SF, Haass C. Amyloid at the cutting edge: Activation of alpha-secretase prevents amyloidogenesis in an Alzheimer disease mouse model. J Clin Invest  2004; 113(10): 1384-7.
[http://dx.doi.org/10.1172/JCI21746] [PMID:  15146234] 
[46] 
Woodward MC. Drug treatments in development for alzheimer’s disease. J Pharm Pract Res  2012; 42(1): 58-65.
[http://dx.doi.org/10.1002/j.2055-2335.2012.tb00133.x] 
[47] 
Mangialasche F, Solomon A, Winblad B, Mecocci P, Kivipelto M. Alzheimer’s disease: Clinical trials and drug development. Lancet Neurol  2010; 9(7): 702-16.
[http://dx.doi.org/10.1016/S1474-4422(10)70119-8] [PMID:  20610346] 
[48] 
Marcade M, Bourdin J, Loiseau N, et al. Etazolate, a neuroprotective drug linking GABA(A) receptor pharmacology to amyloid precursor protein processing. J Neurochem  2008; 106(1): 392-404.
[http://dx.doi.org/10.1111/j.1471-4159.2008.05396.x] [PMID:  18397369] 
[49] 
Drott J, Desire L, Drouin D, Pando M, Haun F. Etazolate improves performance in a foraging and homing task in aged rats. Eur J Pharmacol  2010; 634(1-3): 95-100.
[http://dx.doi.org/10.1016/j.ejphar.2010.02.036] [PMID:  20223232] 
[50] 
Vellas B, Sol O, Snyder PJ, et al. EHT0202 in Alzheimer’s disease: A 3-month, randomized, placebo-controlled, double-blind study. Curr Alzheimer Res  2011; 8(2): 203-12.
[http://dx.doi.org/10.2174/156720511795256053] [PMID:  21222604] 
[51] 
Holthoewer D, Endres K, Schuck F, Hiemke C, Schmitt U, Fahrenholz F. Acitretin, an enhancer of alpha-secretase expression, crosses the blood-brain barrier and is not eliminated by P-glycoprotein. Neurodegener Dis  2012; 10(1-4): 224-8.
[http://dx.doi.org/10.1159/000334300] [PMID:  22301853] 
[52] 
Endres K, Fahrenholz F, Lotz J, et al. Increased CSF APPs-α levels in patients with Alzheimer disease treated with acitretin. Neurology  2014; 83(21): 1930-5.
[http://dx.doi.org/10.1212/WNL.0000000000001017] [PMID:  25344383] 
[53] 
Nikolaev A, McLaughlin T, O’Leary DD, Tessier-Lavigne M. APP binds DR6 to trigger axon pruning and neuron death via distinct caspases. Nature  2009; 457(7232): 981-9.
[http://dx.doi.org/10.1038/nature07767] [PMID:  19225519] 
[54] 
Lahiri DK, Chen D, Maloney B, et al. The experimental Alzheimer’s disease drug posiphen [(+)-phenserine] lowers amyloid-beta peptide levels in cell culture and mice. J Pharmacol Exp Ther  2007; 320(1): 386-96.
[http://dx.doi.org/10.1124/jpet.106.112102] [PMID:  17003227] 
[55] 
Teich AF, Sharma E, Barnwell E, et al. Translational inhibition of APP by Posiphen: Efficacy, pharmacodynamics, and pharmacokinetics in the APP/PS1 mouse. Alzheimers Dement (N Y)  2018; 4(1): 37-45.
[http://dx.doi.org/10.1016/j.trci.2017.12.001] [PMID:  29955650] 
[56] 
Panza F, Solfrizzi V, Imbimbo BP, Tortelli R, Santamato A, Logroscino G. Amyloid-based immunotherapy for Alzheimer’s disease in the time of prevention trials: The way forward. Expert Rev Clin Immunol  2014; 10(3): 405-19.
[http://dx.doi.org/10.1586/1744666X.2014.883921] [PMID:  24490853] 
[57] 
Orgogozo JM, Gilman S, Dartigues JF, et al. Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization. Neurology  2003; 61(1): 46-54.
[http://dx.doi.org/10.1212/01.WNL.0000073623.84147.A8] [PMID:  12847155] 
[58] 
Wiessner C, Wiederhold KH, Tissot AC, et al. The second-generation active Aβ immunotherapy CAD106 reduces amyloid accumulation in APP transgenic mice while minimizing potential side effects. J Neurosci  2011; 31(25): 9323-31.
[http://dx.doi.org/10.1523/JNEUROSCI.0293-11.2011] [PMID:  21697382] 
[59] 
Malonis RJ, Lai JR, Vergnolle O. Peptide-based vaccines: Current progress and future challenges. Chem Rev  2020; 120(6): 3210-29.
[http://dx.doi.org/10.1021/acs.chemrev.9b00472] [PMID:  31804810] 
[60] 
Davtyan H, Ghochikyan A, Petrushina I, et al. Immunogenicity, efficacy, safety, and mechanism of action of epitope vaccine (Lu AF20513) for Alzheimer’s disease: Prelude to a clinical trial. J Neurosci  2013; 33(11): 4923-34.
[http://dx.doi.org/10.1523/JNEUROSCI.4672-12.2013] [PMID:  23486963] 
[61] 
Vandenberghe R, Riviere ME, Caputo A, et al. Active Aβ immunotherapy CAD106 in Alzheimer’s disease: A phase 2b study. Alzheimers Dement (N Y)  2016; 3(1): 10-22.
[http://dx.doi.org/10.1016/j.trci.2016.12.003] [PMID:  29067316] 
[62] 
Farlow MR, Andreasen N, Riviere ME, et al. Long-term treatment with active Aβ immunotherapy with CAD106 in mild Alzheimer’s disease. Alzheimers Res Ther  2015; 7(1): 23.
[http://dx.doi.org/10.1186/s13195-015-0108-3] [PMID:  25918556] 
[63] 
Wang CY, Finstad CL, Walfield AM, et al. Site-specific UBITh amyloid-beta vaccine for immunotherapy of Alzheimer’s disease. Vaccine  2007; 25(16): 3041-52.
[http://dx.doi.org/10.1016/j.vaccine.2007.01.031] [PMID:  17287052] 
[64] 
Wang CY, Wang PN, Chiu MJ, et al. UB-311, a novel UBITh® amyloid β peptide vaccine for mild Alzheimer’s disease. Alzheimers Dement (N Y)  2017; 3(2): 262-72.
[http://dx.doi.org/10.1016/j.trci.2017.03.005] [PMID:  29067332] 
[65] 
Yiannopoulou KG, Papageorgiou SG. Current and future treatments in alzheimer disease: An update. J Cent Nerv Syst Dis  2020; 12: 1179573520907397.
[http://dx.doi.org/10.1177/1179573520907397] [PMID:  32165850] 
[66] 
Lacosta AM, Insua D, Badi H, Pesini P, Sarasa M. Neurofibrillary tangles of Aβx-40 in alzheimer’s disease brains. J Alzheimers Dis  2017; 58(3): 661-7.
[http://dx.doi.org/10.3233/JAD-170163] [PMID:  28453491] 
[67] 
Lacosta AM, Pascual-Lucas M, Pesini P, et al. Safety, tolerability and immunogenicity of an active anti-Aβ40 vaccine (ABvac40) in patients with Alzheimer’s disease: A randomised, double-blind, placebo-controlled, phase I trial. Alzheimers Res Ther  2018; 10(1): 12.
[http://dx.doi.org/10.1186/s13195-018-0340-8] [PMID:  29378651] 
[68] 
Anand P, Singh B. A review on cholinesterase inhibitors for Alzheimer’s disease. Arch Pharm Res  2013; 36(4): 375-99.
[http://dx.doi.org/10.1007/s12272-013-0036-3] [PMID:  23435942] 
[69] 
van Dyck CH. Anti-amyloid-β monoclonal antibodies for alzheimer’s disease: Pitfalls and promise. Biol Psychiatry  2018; 83(4): 311-9.
[http://dx.doi.org/10.1016/j.biopsych.2017.08.010] [PMID:  28967385] 
[70] 
Farlow M, Arnold SE, van Dyck CH, et al. Safety and biomarker effects of solanezumab in patients with Alzheimer’s disease. Alzheimers Dement  2012; 8(4): 261-71.
[http://dx.doi.org/10.1016/j.jalz.2011.09.224] [PMID:  22672770] 
[71] 
Siemers ER, Sundell KL, Carlson C, et al. Phase 3 solanezumab trials: Secondary outcomes in mild Alzheimer’s disease patients. Alzheimers Dement  2016; 12(2): 110-20.
[http://dx.doi.org/10.1016/j.jalz.2015.06.1893] [PMID:  26238576] 
[72] 
Tarrant SD, Bardach SH, Bates K, et al. The effectiveness of small-group community-based information sessions on clinical trial recruitment for secondary prevention of alzheimer’s disease. Alzheimer Dis Assoc Disord  2017; 31(2): 141-5.
[http://dx.doi.org/10.1097/WAD.0000000000000151] [PMID:  27213625] 
[73] 
Zhao J, Nussinov R, Ma B. Mechanisms of recognition of amyloid-β (Aβ) monomer, oligomer, and fibril by homologous antibodies. J Biol Chem  2017; 292(44): 18325-43.
[http://dx.doi.org/10.1074/jbc.M117.801514] [PMID:  28924036] 
[74] 
Adolfsson O, Pihlgren M, Toni N, et al. An effector-reduced anti-β-amyloid (Aβ) antibody with unique aβ binding properties promotes neuroprotection and glial engulfment of Aβ. J Neurosci  2012; 32(28): 9677-89.
[http://dx.doi.org/10.1523/JNEUROSCI.4742-11.2012] [PMID:  22787053] 
[75] 
Salloway S, Honigberg LA, Cho W, et al. Amyloid positron emission tomography and cerebrospinal fluid results from a crenezumab anti-amyloid-beta antibody double-blind, placebo-controlled, randomized phase II study in mild-to-moderate Alzheimer’s disease (BLAZE). Alzheimers Res Ther  2018; 10(1): 96.
[http://dx.doi.org/10.1186/s13195-018-0424-5] [PMID:  30231896] 
[76] 
Cummings JL, Cohen S, van Dyck CH, et al. ABBY: A phase 2 randomized trial of crenezumab in mild to moderate Alzheimer disease. Neurology  2018; 90(21): e1889-97.
[http://dx.doi.org/10.1212/WNL.0000000000005550] [PMID:  29695589] 
[77] 
Ghisays V, Lopera F, Goradia DD, et al. PET evidence of preclinical cerebellar amyloid plaque deposition in autosomal dominant Alzheimer’s disease-causing Presenilin-1 E280A mutation carriers. Neuroimage Clin  2021; 31: 102749.
[http://dx.doi.org/10.1016/j.nicl.2021.102749] [PMID:  34252876] 
[78] 
Ostrowitzki S, Lasser RA, Dorflinger E, et al. A phase III randomized trial of gantenerumab in prodromal Alzheimer’s disease. Alzheimers Res Ther  2017; 9(1): 95.
[http://dx.doi.org/10.1186/s13195-017-0318-y] [PMID:  29221491] 
[79] 
Mukhopadhyay S, Banerjee D. A primer on the evolution of aducanumab: The first antibody approved for treatment of alzheimer’s disease. J Alzheimers Dis  2021; 83(4): 1537-52.
[http://dx.doi.org/10.3233/JAD-215065] [PMID:  34366359] 
[80] 
Sevigny J, Chiao P, Bussière T, et al. The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease. Nature  2016; 537(7618): 50-6.
[http://dx.doi.org/10.1038/nature19323] [PMID:  27582220] 
[81] 
Loureiro JC, Pais MV, Stella F, et al. Passive antiamyloid immunotherapy for Alzheimer’s disease. Curr Opin Psychiatry  2020; 33(3): 284-91.
[http://dx.doi.org/10.1097/YCO.0000000000000587] [PMID:  32040044] 
[82] 
 BIIB037 in Prodromal or Mild Alzheimer’s Disease Available from: https://www.nia.nih.gov/alzheimers/clinical-trials/biib037-prodromal-or-mild-alzheimers-disease Accessed on September 27, 2021.
[83] 
 FDA accepts biogen’s aducanumab biologics license application for alzheimer’s disease with priority review. Available from: https://investors.biogen.com/news-releases/news-release-details/fda-accepts-biogens-aducanumab-biologics-license-application Accessed on September 27, 2021.
[84] 
Logovinsky V, Satlin A, Lai R, et al. Safety and tolerability of BAN2401--a clinical study in Alzheimer’s disease with a protofibril selective Aβ antibody. Alzheimers Res Ther  2016; 8(1): 14.
[http://dx.doi.org/10.1186/s13195-016-0181-2] [PMID:  27048170] 
[85] 
Swanson CJ, Zhang Y, Dhadda S, et al. A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer’s disease with lecanemab, an anti-Aβ protofibril antibody. Alzheimers Res Ther  2021; 13(1): 80.
[http://dx.doi.org/10.1186/s13195-021-00813-8] [PMID:  33865446] 
[86] 
 Investigational Alzheimer’s Disease Therapy Lecanemab Granted FDA Fast Track Designation. Available from: http://media.biogen.com/news-releases/news-release-details/investigational-alzheimers-disease-therapy-lecanemab-granted-fda Accessed on February 22 2022.
[87] 
Lowe SL, Willis BA, Hawdon A, et al. Donanemab (LY3002813) dose-escalation study in Alzheimer’s disease. Alzheimers Dement (N Y)  2021; 7(1): e12112.
[http://dx.doi.org/10.1002/trc2.12112] [PMID:  33614890] 
[88] 
Lowe SL, Duggan Evans C, Shcherbinin S, et al. Donanemab (LY3002813) phase 1b study in alzheimer’s disease: rapid and sustained reduction of brain amyloid measured by florbetapir F18 imaging. J Prev Alzheimers Dis  2021; 8(4): 414-24.
[PMID:  34585215] 
[89] 
Espay AJ. Donanemab in early alzheimer’s disease. N Engl J Med  2021; 385(7): 666-7.
[http://dx.doi.org/10.1056/NEJMc2109455] [PMID:  34379933] 
[90] 
 Lilly's donanemab receives U.S. FDA's Breakthrough Therapy designation for treatment of Alzheimer's disease. Available from: https://investor.lilly.com/news-releases/news-release-details/lillys-donanemab-receives-us-fdas-breakthrough-therapy Accessed on February 22, 2022.
[91] 
Kroth H, Sreenivasachary N, Hamel A, et al. Synthesis and structure-activity relationship of 2,6-disubstituted pyridine derivatives as inhibitors of β-amyloid-42 aggregation. Bioorg Med Chem Lett  2016; 26(14): 3330-5.
[http://dx.doi.org/10.1016/j.bmcl.2016.05.040] [PMID:  27256911] 
[92] 
Manzano S, Agüera L, Aguilar M, Olazarán J. A review on tramiprosate (homotaurine) in alzheimer’s disease and other neurocognitive disorders. Front Neurol  2020; 11: 614.
[http://dx.doi.org/10.3389/fneur.2020.00614] [PMID:  32733362] 
[93] 
Gervais F, Paquette J, Morissette C, et al. Targeting soluble Abeta peptide with Tramiprosate for the treatment of brain amyloidosis. Neurobiol Aging  2007; 28(4): 537-47.
[http://dx.doi.org/10.1016/j.neurobiolaging.2006.02.015] [PMID:  16675063] 
[94] 
Aisen PS, Saumier D, Briand R, et al. A Phase II study targeting amyloid-beta with 3APS in mild-to-moderate Alzheimer disease. Neurology  2006; 67(10): 1757-63.
[http://dx.doi.org/10.1212/01.wnl.0000244346.08950.64] [PMID:  17082468] 
[95] 
Gauthier S, Aisen PS, Ferris SH, et al. Effect of tramiprosate in patients with mild-to-moderate Alzheimer’s disease: Exploratory analyses of the MRI sub-group of the Alphase study. J Nutr Health Aging  2009; 13(6): 550-7.
[http://dx.doi.org/10.1007/s12603-009-0106-x] [PMID:  19536424] 
[96] 
Hey JA, Yu JY, Versavel M, et al. Clinical pharmacokinetics and safety of ALZ-801, a novel prodrug of tramiprosate in development for the treatment of alzheimer’s disease. Clin Pharmacokinet  2018; 57(3): 315-33.
[http://dx.doi.org/10.1007/s40262-017-0608-3] [PMID:  29063518] 
[97] 
Kocis P, Tolar M, Yu J, et al. Elucidating the Aβ42 anti-aggregation mechanism of action of tramiprosate in alzheimer’s disease: integrating molecular analytical methods, pharmacokinetic and clinical data. CNS Drugs  2017; 31(6): 495-509.
[http://dx.doi.org/10.1007/s40263-017-0434-z] [PMID:  28435985] 
[98] 
Hey JA, Kocis P, Hort J, et al. Discovery and identification of an endogenous metabolite of tramiprosate and its prodrug ALZ-801 that inhibits beta amyloid oligomer formation in the human brain. CNS Drugs  2018; 32(9): 849-61.
[http://dx.doi.org/10.1007/s40263-018-0554-0] [PMID:  30076539] 
[99] 
Jawhar S, Wirths O, Bayer TA. Pyroglutamate amyloid-β (Aβ): A hatchet man in Alzheimer disease. J Biol Chem  2011; 286(45): 38825-32.
[http://dx.doi.org/10.1074/jbc.R111.288308] [PMID:  21965666] 
[100] 
Hoffmann T, Rahfeld JU, Schenk M, et al. Combination of the glutaminyl cyclase inhibitor PQ912 (varoglutamstat) and the murine monoclonal antibody PBD-C06 (m6) shows additive effects on brain Aβ pathology in transgenic mice. Int J Mol Sci  2021; 22(21): 11791.
[http://dx.doi.org/10.3390/ijms222111791] [PMID:  34769222] 
[101] 
Scheltens P, Hallikainen M, Grimmer T, et al. Safety, tolerability and efficacy of the glutaminyl cyclase inhibitor PQ912 in Alzheimer’s disease: Results of a randomized, double-blind, placebo-controlled phase 2a study. Alzheimers Res Ther  2018; 10(1): 107.
[http://dx.doi.org/10.1186/s13195-018-0431-6] [PMID:  30309389] 
[102] 
Wang S, Li J, Xia W, Geng M. A marine-derived acidic oligosaccharide sugar chain specifically inhibits neuronal cell injury mediated by beta-amyloid-induced astrocyte activation in vitro. Neurol Res  2007; 29(1): 96-102.
[http://dx.doi.org/10.1179/174313206X152483] [PMID:  17427283] 
[103] 
Wang X, Sun G, Feng T, et al. Sodium oligomannate therapeutically remodels gut microbiota and suppresses gut bacterial amino acids-shaped neuroinflammation to inhibit Alzheimer’s disease progression. Cell Res  2019; 29(10): 787-803.
[http://dx.doi.org/10.1038/s41422-019-0216-x] [PMID:  31488882] 
[104] 
Wang T, Kuang W, Chen W, et al. A phase II randomized trial of sodium oligomannate in Alzheimer’s dementia. Alzheimers Res Ther  2020; 12(1): 110.
[http://dx.doi.org/10.1186/s13195-020-00678-3] [PMID:  32928279] 
[105] 
 China approves seaweed sugar as first new alzheimer’s drug in 17 Years. Available from: https://www.alzforum.org/news/research-news/china-approves-seaweed-sugar-first-new-alzheimers-drug-17-years Accessed on September 27, 2021.
[106] 
Zhang Z, Miah M, Culbreth M, Aschner M. Autophagy in neurodegenerative diseases and metal neurotoxicity. Neurochem Res  2016; 41(1-2): 409-22.
[http://dx.doi.org/10.1007/s11064-016-1844-x] [PMID:  26869037] 
[107] 
Matlack KE, Tardiff DF, Narayan P, et al. Clioquinol promotes the degradation of metal-dependent amyloid-β (Aβ) oligomers to restore endocytosis and ameliorate Aβ toxicity. Proc Natl Acad Sci USA  2014; 111(11): 4013-8.
[http://dx.doi.org/10.1073/pnas.1402228111] [PMID:  24591589] 
[108] 
Prajakta Deshpande, Neha Gogia, Amit Singh. Exploring the efficacy of natural products in alleviating Alzheimer’s disease. Neural Regen Res  2019; 14(08): 35-43.
[109] 
Ashrafizadeh M, Zarrabi A, Najafi M, Samarghandian S, Mohammadinejad R, Ahn KS. Resveratrol targeting tau proteins, amyloid-beta aggregations, and their adverse effects: An updated review. Phytother Res  2020; 34(11): 2867-88.
[http://dx.doi.org/10.1002/ptr.6732] [PMID:  32491273] 
[110] 
Karuppagounder SS, Pinto JT, Xu H, Chen HL, Beal MF, Gibson GE. Dietary supplementation with resveratrol reduces plaque pathology in a transgenic model of Alzheimer’s disease. Neurochem Int  2009; 54(2): 111-8.
[http://dx.doi.org/10.1016/j.neuint.2008.10.008] [PMID:  19041676] 
[111] 
Li F, Gong Q, Dong H, Shi J. Resveratrol, a neuroprotective supplement for Alzheimer’s disease. Curr Pharm Des  2012; 18(1): 27-33.
[http://dx.doi.org/10.2174/138161212798919075] [PMID:  22211686] 
[112] 
Sun XY, Dong QX, Zhu J, et al. Resveratrol rescues tau-induced cognitive deficits and neuropathology in a mouse model of tauopathy. Curr Alzheimer Res  2019; 16(8): 710-22.
[http://dx.doi.org/10.2174/1567205016666190801153751] [PMID:  31368873] 
[113] 
Turner RS, Thomas RG, Craft S, et al. A randomized, double-blind, placebo-controlled trial of resveratrol for Alzheimer disease. Neurology  2015; 85(16): 1383-91.
[http://dx.doi.org/10.1212/WNL.0000000000002035] [PMID:  26362286] 
[114] 
Fu X, Zhang J, Guo L, et al. Protective role of luteolin against cognitive dysfunction induced by chronic cerebral hypoperfusion in rats. Pharmacol Biochem Behav  2014; 126: 122-30.
[http://dx.doi.org/10.1016/j.pbb.2014.09.005] [PMID:  25220684] 
[115] 
Zhou F, Chen S, Xiong J, Li Y, Qu L. Luteolin reduces zinc-induced tau phosphorylation at Ser262/356 in an ROS-dependent manner in SH-SY5Y cells. Biol Trace Elem Res  2012; 149(2): 273-9.
[http://dx.doi.org/10.1007/s12011-012-9411-z] [PMID:  22528780] 
[116] 
Liu R, Meng F, Zhang L, et al. Luteolin isolated from the medicinal plant Elsholtzia rugulosa (Labiatae) prevents copper-mediated toxicity in β-amyloid precursor protein Swedish mutation overexpressing SH-SY5Y cells. Molecules  2011; 16(3): 2084-96.
[http://dx.doi.org/10.3390/molecules16032084] [PMID:  21368720] 
[117] 
Khan H, Ullah H, Aschner M, Cheang WS, Akkol EK. Neuroprotective effects of quercetin in alzheimer’s disease. Biomolecules  2019; 10(1): E59.
[http://dx.doi.org/10.3390/biom10010059] [PMID:  31905923] 
[118] 
Zaplatic E, Bule M, Shah SZA, Uddin MS, Niaz K. Molecular mechanisms underlying protective role of quercetin in attenuating Alzheimer’s disease. Life Sci  2019; 224: 109-19.
[http://dx.doi.org/10.1016/j.lfs.2019.03.055] [PMID:  30914316] 
[119] 
Li YL, Guo H, Zhao YQ, Li AF, Ren YQ, Zhang JW. Quercetin protects neuronal cells from oxidative stress and cognitive degradation induced by amyloid β-peptide treatment. Mol Med Rep  2017; 16(2): 1573-7.
[http://dx.doi.org/10.3892/mmr.2017.6704] [PMID:  28586024] 
[120] 
Reddy PH, Manczak M, Yin X, et al. Protective effects of Indian spice curcumin against amyloid-β in alzheimer’s disease. J Alzheimers Dis  2018; 61(3): 843-66.
[http://dx.doi.org/10.3233/JAD-170512] [PMID:  29332042] 
[121] 
Su IJ, Chang HY, Wang HC, Tsai KJ. A curcumin analog exhibits multiple biologic effects on the pathogenesis of alzheimer’s disease and improves behavior, inflammation, and β-amyloid accumulation in a mouse model. Int J Mol Sci  2020; 21(15): E5459.
[http://dx.doi.org/10.3390/ijms21155459] [PMID:  32751716] 
[122] 
Wang HY, Bakshi K, Frankfurt M, et al. Reducing amyloid-related Alzheimer’s disease pathogenesis by a small molecule targeting filamin A. J Neurosci  2012; 32(29): 9773-84.
[http://dx.doi.org/10.1523/JNEUROSCI.0354-12.2012] [PMID:  22815492] 
[123] 
Wang HY, Lee KC, Pei Z, Khan A, Bakshi K, Burns LH. PTI-125 binds and reverses an altered conformation of filamin A to reduce Alzheimer’s disease pathogenesis. Neurobiol Aging  2017; 55: 99-114.
[http://dx.doi.org/10.1016/j.neurobiolaging.2017.03.016] [PMID:  28438486] 
[124] 
Wang HY, Pei Z, Lee KC, et al. PTI-125 reduces biomarkers of alzheimer’s disease in patients. J Prev Alzheimers Dis  2020; 7(4): 256-64.
[PMID:  32920628] 
[125] 
Álvarez X, Linares C, Masliah E. Combination drug therapy for the treatment of alzheimer’s disease. Eur Neurol Rev  2012; 7(2): 92-101.
[http://dx.doi.org/10.17925/ENR.2012.07.02.92] 
[126] 
Gavrilova SI, Alvarez A. Cerebrolysin in the therapy of mild cognitive impairment and dementia due to Alzheimer’s disease: 30 years of clinical use. Med Res Rev  2021; 41(5): 2775-803.
[http://dx.doi.org/10.1002/med.21722] [PMID:  32808294] 
[127] 
Cummings J, Fox N. Defining disease modifying therapy for alzheimer’s disease. J Prev Alzheimers Dis  2017; 4(2): 109-15.
[http://dx.doi.org/10.14283/jpad.2017.12] [PMID:  29071250] 
[128] 
Salloway SP, Sevingy J, Budur K, et al. Advancing combination therapy for Alzheimer’s disease. Alzheimers Dement (N Y)  2020; 6(1): e12073.
[http://dx.doi.org/10.1002/trc2.12073] [PMID:  33043108] 
[129] 
Cummings JL, Tong G, Ballard C. Treatment combinations for alzheimer’s disease: Current and future pharmacotherapy options. J Alzheimers Dis  2019; 67(3): 779-94.
[http://dx.doi.org/10.3233/JAD-180766] [PMID:  30689575] 
[130] 
Panza F, Lozupone M, Logroscino G, Imbimbo BP. A critical appraisal of amyloid-β-targeting therapies for Alzheimer disease. Nat Rev Neurol  2019; 15(2): 73-88.
[http://dx.doi.org/10.1038/s41582-018-0116-6] [PMID:  30610216] 
[131] 
Tolar M, Abushakra S, Sabbagh M. The path forward in Alzheimer’s disease therapeutics: Reevaluating the amyloid cascade hypothesis. Alzheimers Dement  2020; 16(11): 1553-60.
[http://dx.doi.org/10.1016/j.jalz.2019.09.075] [PMID:  31706733] 
Rights & Permissions Print Cite
Article Metrics
72
1
Journal Information
For Authors
For Editors
For Reviewers
Explore Articles
Open Access
Open Access Articles
For Visitors
DOI https://dx.doi.org/10.2174/1389450123666220421124030	Print ISSN 1389-4501
Publisher Name Bentham Science Publisher	Online ISSN 1873-5592
当代药物靶点

淀粉样蛋白β靶向治疗阿尔茨海默病的方法：漫长的未来

摘要

图形摘要

Drug-Targeted Approach with Polymer Nanocomposites for Improved Therapeutics

New drug therapy for eye diseases

RNA Molecules in the Treatment of Human Diseases

Therapeutic Chemical and RNA Design with Artificial Intelligence

当代药物靶点

淀粉样蛋白β靶向治疗阿尔茨海默病的方法：漫长的未来

摘要

图形摘要

Call for Papers in Thematic Issues

Drug-Targeted Approach with Polymer Nanocomposites for Improved Therapeutics

New drug therapy for eye diseases

RNA Molecules in the Treatment of Human Diseases

Therapeutic Chemical and RNA Design with Artificial Intelligence

Related Journals

Related Books

Related Articles
